They highlighted several limitations of the study, including a risk for biases associated with modeling analyses, obtaining data from studies primarily involving white men, and bisphosphonate as the only assumed treatment.
“The good news is that we have easy, accessible, low-cost ways to screen men, and we have effective treatments available for men. Our study demonstrates that routine osteoporosis screening for U.S. middle-aged (50 or 60 years) and older men is likely to be effective and of good value for preventing future fractures and improving health outcomes,” Dr. Nayak said.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute on Aging supported this research. Dr. Greenspan reports serving on the scientific advisory board for Merck.
